title: Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status.
abstract: Forty-six eligible women with metastatic endometrial cancer were randomly allocated to receive monthly cycles of either CAF (cyclophosphamide, adriamycin, 5-fluorouracil) or CAF plus Provera 200 mg daily for 3 weeks followed cyclically by Tamoxifen 20 mg daily for 3 weeks. Overall response rates of 15 and 43% were seen with CAF and CAF plus hormonal therapy. Using a multivariate analysis of the results, this difference is significant (P value 0.05). In 8 patients with operable endometrial cancer, negative estrogen receptor concentration (ER less than 15 fmole/mg protein) and Grade 3 disease, the clinical course was aggressive in 4 patients with systemic and local relapse. In 10 other similar patients (negative ER and Grade 3) who received adjuvant cyclical hormonal therapy only 1 relapsed and the other 9 are disease-free for an average of more than 31 months. Sequential cyclical hormonal therapy with ER and progesterone receptor analysis has a place in the management of endometrial carcinoma.
authors.affiliation: Le Réseau Interhospitalier de Cancérologie, Université de Montréal (RICUM), Quebec, Canada.
authors.forename: J
authors.initials: J
authors.lastname: Ayoub
authors.forename: P
authors.initials: P
authors.lastname: Audet-Lapointe
authors.forename: Y
authors.initials: Y
authors.lastname: Méthot
authors.forename: J
authors.initials: J
authors.lastname: Hanley
authors.forename: R
authors.initials: R
authors.lastname: Beaulieu
authors.forename: R
authors.initials: R
authors.lastname: Chemaly
authors.forename: A
authors.initials: A
authors.lastname: Cormier
authors.forename: J P
authors.initials: JP
authors.lastname: Déry
authors.forename: P
authors.initials: P
authors.lastname: Drouin
authors.forename: P
authors.initials: P
authors.lastname: Gauthier
mesh_terms: D000230:Adenocarcinoma / Q000032:analysis / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011446:Prospective Studies; D011897:Random Allocation; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D012074:Remission Induction; D013629:Tamoxifen / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000032:analysis / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy
chemical_list: D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen; D004317:Doxorubicin; D003520:Cyclophosphamide; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; D005472:Fluorouracil